GLUSAMIN 1500 Milligram Film Coated Tablet

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

GLUCOSAMINE SULFATE SODIUM CHLORIDE

제공처:

FMC Pharma Ltd

INN (국제 이름):

GLUCOSAMINE SULFATE SODIUM CHLORIDE

복용량:

1500 Milligram

약제 형태:

Film Coated Tablet

처방전 유형:

Product subject to prescription which may be renewed (B)

승인 상태:

Authorised

승인 날짜:

0000-00-00

환자 정보 전단

PACKAGE LEAFLET: INFORMATION FOR THE USER 

GLUSAMIN 1500 MG FILM-COATED TABLETS 

GLUCOSAMINE SULFATE 

READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE. 
  Keep this leaflet. You may need to read it again. 
  If you have any further questions, ask your doctor or
pharmacist. 
  This medicine has been prescribed for you. Do not pass it on
to others. It may harm them, 
even if their symptoms are the same as yours. 
  If any of the side effects get serious, or if you notice any
side effect not listed in this 
leaflet, please tell your doctor or pharmacist. 

WHAT IS IN THIS LEAFLET: 
1. 
What Glusamin is and what it is used for 
2. 
What you need to know before you take Glusamin 
3. 
How to take Glusamin 
4. 
Possible side effects 
5. 
How to store Glusamin 
6. 
Contents of the pack and other information 

1. 
WHAT GLUSAMIN IS AND WHAT IT IS USED FOR 

Glusamin belongs to a group of medicines called other
anti-inflammatory and anti-rheumatic 
agents, non steroids. 
Glusamin is used for the relief of symptoms of mild to moderate
osteoarthritis of the knee. 

Osteoarthritis is a type of joint degeneration that generates
symptoms such as stiffness (after 
sleep or long rest) and pain at motion (e.g. when climbing the stairs
or walking along uneven 
surfaces). 

2. 
WHAT YOU NEED TO KNOW BEFORE YOU TAKE GLUSAMIN 
DO NOT TAKE GLUSAMIN 
- 
If you are allergic (hypersensitive) to: 
-  Glucosamine or to any of the other ingredients of Glusamin (see
Section 6 “Further 
Information”) 
-  Shellfish, since Glusamin is manufactured from shellfish. 

WARNINGS AND PRECAUTIONS 

TAKE SPECIAL CARE WITH GLUSAMIN IF YOU 
- 
Suffer from impaired glucose tolerance.  More frequent controls of
your blood glucose 
levels may be necessary when starting treatment with Glusamin 
- 
Have kidney or liver dysfunction, since no studies have been
performed in such patients 
dose recommendations cannot

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Glusamin 1500mg Film-Coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 1884mg glucosamine sulfate sodium chloride
equivalent to 1500 mg glucosamine sulfate or 1178mg glucosamine.
Excipients with known effect:
Each tablet contains 151.8 mg (6.6mmol) of sodium.
Lactose monohydrate 6.0 mg
Lecithin soya (E322)
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet
Off-white oblong shaped film-coated tablet, 9.5 x 21mm
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Glusamin tablets are indicated for relief of symptoms in mild to moderate osteoarthritis of the knee.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Method of Administration:
Glusamin tablets should be swallowed whole.
Tablets can be taken with or without food.
_Adults and the elderly_:
One Glusamin tablet should be taken once daily.
Posology:
Glucosamine is not indicated for the treatment of acute painful symptoms. Relief of symptoms (especially pain relief)
may not be experienced until after several weeks of treatment and in some cases even longer. If no relief of symptoms
is experienced after 2-3 months, continued treatment with glucosamine should be re-evaluated.
Additional information on special populations:
_Children/adolescents:_
Safety and efficacy has not been established in children and adolescents, therefore, Glucosamine sulfate tablets should
not be used in persons under the age of 18 years.
_Elderly_
No specific studies have been performed in the elderly, but according to clinical experience dosage adjustment is not
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 08/07/2014_
_CRN 212